Curated multi-peptide research blend of lyophilized reference materials supplied with batch-specific Certificate of Analysis. For in-vitro laboratory research use only. Not for human or veterinary use.

Research Use Only

Sold strictly as a lyophilized analytical reference standard for in-vitro laboratory research by qualified professionals. Not for use in any living organism. Not a drug, food, cosmetic, or dietary supplement. No medical, therapeutic, diagnostic, or health claims are made. No dosing or administration guidance is provided.

Research Overview

A dual metabolic blend — Retatrutide 20 mg paired with Tirzepatide 40 mg in one 60 mg vial.

BURN combines two of the most-studied incretin peptides in current metabolic literature. Retatrutide engages the GLP-1, GIP, and glucagon receptors, while Tirzepatide acts as a dual GLP-1 / GIP agonist. Researchers use combined preparations like this to study overlapping receptor pathways in a single reference material. Published work is early-stage and reflects only what was measured under those study conditions.

What studies have looked at

Overlapping GLP-1, GIP, and glucagon receptor activity
Appetite and satiety signaling pathways
Glucose handling in research models
Energy use and substrate metabolism markers

Research Information

The information above is provided for educational and research reference purposes only. These products are intended for laboratory research use only and are not approved for human consumption. Statements on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Certificate of Analysis

Every batch of BURN 60mg is independently characterized by HPLC and mass spectrometry. The full COA — including chromatogram, mass spec data, net purity, and net content verification — is available on request for the lot you receive.

View Certificates of Analysis Request Batch COA